The Pharmaceutical Journal
Vol 273 No 7306 p5
3 July 2004

This article
Reprint   Photocopy

  Acrobat Reader

News summary

MHRA asks for evidence for co-proxamol risks or benefits

The Medicines and Healthcare products Regulatory Agency has issued a request for further evidence from clinical trials or observational data regarding the risks and benefits of co-proxamol, as part of an ongoing review by the Committee on Safety of Medicines. The MHRA particularly wants to identify any patient groups in whom the risk-benefit balance is favourable.

The request, current evidence and response form can be accessed here